TPD52: A Novel Vaccine Target for Prostate Cancer
Abstract
The overall goal of this Award is to test the efficacy of TPD52-based vaccines in the TRAMP murine model of prostate cancer, and to characterize vaccine induced mechanisms of tumor immunity. We have continued our evaluation of the ability of TPD52-DNA and/or TPD52-protein based vaccines to induce immune responses capable of rejecting the formation of subcutaneous tumors following challenge with prostate-derived TRAMP-C1 or TRAMP-C2 tumor cells. Over the past 12 months we have made the following significant findings or accomplishments; First, DNA vaccines encoding the human TPD25 (hD52) induced increased protection from not only primary challenge, but secondary challenge with a distinct TRAMP-C tumor, compared to murine TPD52 (mD52)-DNA based vaccines suggesting the hD52 xeno-antigen was capable of inducing more effective memory responses. Second, the cytokine profile from vaccine induced T cells indicated a cellular Th1-type response that was important for tumor protection. Third, in vivo inhibition of TGF -1 with TPD52-protein vaccination increased protection from tumor challenge demonstrating a regulatory role for TGF -1. Finally, T cell cytokine analyses revealed the presence of a population of CD8+ MHC-I-restricted T cells that secrete IL-10 in an antigen-specific manner, suggesting a novel role for CD8+ Treg cells in suppressing TPD52-based vaccination in our model.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2010
- Accession Number
- ADA535025
Entities
People
- Jennifer D. Bright
- Robert K. Bright
Organizations
- Texas Tech University Health Sciences Center